| Jean-marie R Ebrahimi, MD | |
|
7301 Ohms Lane, Ste 650, Edina, MN 55439 | |
| (952) 835-9880 | |
| (952) 857-1554 |
| Full Name | Jean-marie R Ebrahimi |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 7301 Ohms Lane, Edina, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801863022 | NPI | - | NPPES |
| 26683 | Other | MN | MN MEDICAL LICENSE |
| 595385500 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 26683 (Minnesota) | Primary |
| Entity Name | Healtheast Woodwinds Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356309322 PECOS PAC ID: 9638082563 Enrollment ID: O20031107000110 |
News Archive
Researchers at the University at Buffalo and the University of Pennsylvania were the first to demonstrate that two intracellular events, both stimulated by the same cell receptor, can provoke different behaviors in mammals.
In a preview of a Jan. 24 magazine article, The New York Times reports on Senate Majority Leader Harry Reid's struggle to keep members of his caucus in line on health reform. In December, for instance, Sen. Joseph Lieberman, D-Conn., told a talk show host he would not support the health overhaul plan without significant changes, surprising the majority leader.
A review of contemporary grading systems for prostate cancer has found that modernization of the Gleason grading system results in more accurate grading for radical prostatectomy than older systems.
Scientists from Duke-NUS Medical School have derived a structural model of a transporter at the blood-brain barrier called Mfsd2a. This is the first molecular model of this critical transporter, and could prove important for the development of therapeutic agents that need to be delivered to the brain -- across the blood-brain barrier. In future, this could help treat neurological disorders such as glioblastoma.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths. Deferoxamine Mesylate is therapeutically equivalent to the reference-listed drug Desferal®, which is marketed by the innovator Novartis.
› Verified 7 days ago
| Entity Name | Healtheast St John's Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447218482 PECOS PAC ID: 9234035742 Enrollment ID: O20031208000320 |
News Archive
Researchers at the University at Buffalo and the University of Pennsylvania were the first to demonstrate that two intracellular events, both stimulated by the same cell receptor, can provoke different behaviors in mammals.
In a preview of a Jan. 24 magazine article, The New York Times reports on Senate Majority Leader Harry Reid's struggle to keep members of his caucus in line on health reform. In December, for instance, Sen. Joseph Lieberman, D-Conn., told a talk show host he would not support the health overhaul plan without significant changes, surprising the majority leader.
A review of contemporary grading systems for prostate cancer has found that modernization of the Gleason grading system results in more accurate grading for radical prostatectomy than older systems.
Scientists from Duke-NUS Medical School have derived a structural model of a transporter at the blood-brain barrier called Mfsd2a. This is the first molecular model of this critical transporter, and could prove important for the development of therapeutic agents that need to be delivered to the brain -- across the blood-brain barrier. In future, this could help treat neurological disorders such as glioblastoma.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths. Deferoxamine Mesylate is therapeutically equivalent to the reference-listed drug Desferal®, which is marketed by the innovator Novartis.
› Verified 7 days ago
| Entity Name | County Of Meeker |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083221816 PECOS PAC ID: 0840109740 Enrollment ID: O20040216000811 |
News Archive
Researchers at the University at Buffalo and the University of Pennsylvania were the first to demonstrate that two intracellular events, both stimulated by the same cell receptor, can provoke different behaviors in mammals.
In a preview of a Jan. 24 magazine article, The New York Times reports on Senate Majority Leader Harry Reid's struggle to keep members of his caucus in line on health reform. In December, for instance, Sen. Joseph Lieberman, D-Conn., told a talk show host he would not support the health overhaul plan without significant changes, surprising the majority leader.
A review of contemporary grading systems for prostate cancer has found that modernization of the Gleason grading system results in more accurate grading for radical prostatectomy than older systems.
Scientists from Duke-NUS Medical School have derived a structural model of a transporter at the blood-brain barrier called Mfsd2a. This is the first molecular model of this critical transporter, and could prove important for the development of therapeutic agents that need to be delivered to the brain -- across the blood-brain barrier. In future, this could help treat neurological disorders such as glioblastoma.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths. Deferoxamine Mesylate is therapeutically equivalent to the reference-listed drug Desferal®, which is marketed by the innovator Novartis.
› Verified 7 days ago
| Entity Name | Emergency Care Consultants Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669422788 PECOS PAC ID: 5496640161 Enrollment ID: O20040220000380 |
News Archive
Researchers at the University at Buffalo and the University of Pennsylvania were the first to demonstrate that two intracellular events, both stimulated by the same cell receptor, can provoke different behaviors in mammals.
In a preview of a Jan. 24 magazine article, The New York Times reports on Senate Majority Leader Harry Reid's struggle to keep members of his caucus in line on health reform. In December, for instance, Sen. Joseph Lieberman, D-Conn., told a talk show host he would not support the health overhaul plan without significant changes, surprising the majority leader.
A review of contemporary grading systems for prostate cancer has found that modernization of the Gleason grading system results in more accurate grading for radical prostatectomy than older systems.
Scientists from Duke-NUS Medical School have derived a structural model of a transporter at the blood-brain barrier called Mfsd2a. This is the first molecular model of this critical transporter, and could prove important for the development of therapeutic agents that need to be delivered to the brain -- across the blood-brain barrier. In future, this could help treat neurological disorders such as glioblastoma.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths. Deferoxamine Mesylate is therapeutically equivalent to the reference-listed drug Desferal®, which is marketed by the innovator Novartis.
› Verified 7 days ago
| Entity Name | Children's Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932208808 PECOS PAC ID: 2668370966 Enrollment ID: O20040406000939 |
News Archive
Researchers at the University at Buffalo and the University of Pennsylvania were the first to demonstrate that two intracellular events, both stimulated by the same cell receptor, can provoke different behaviors in mammals.
In a preview of a Jan. 24 magazine article, The New York Times reports on Senate Majority Leader Harry Reid's struggle to keep members of his caucus in line on health reform. In December, for instance, Sen. Joseph Lieberman, D-Conn., told a talk show host he would not support the health overhaul plan without significant changes, surprising the majority leader.
A review of contemporary grading systems for prostate cancer has found that modernization of the Gleason grading system results in more accurate grading for radical prostatectomy than older systems.
Scientists from Duke-NUS Medical School have derived a structural model of a transporter at the blood-brain barrier called Mfsd2a. This is the first molecular model of this critical transporter, and could prove important for the development of therapeutic agents that need to be delivered to the brain -- across the blood-brain barrier. In future, this could help treat neurological disorders such as glioblastoma.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths. Deferoxamine Mesylate is therapeutically equivalent to the reference-listed drug Desferal®, which is marketed by the innovator Novartis.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jean-marie R Ebrahimi, MD 7301 Ohms Lane, Ste 650, Edina, MN 55439 Ph: (952) 835-9880 | Jean-marie R Ebrahimi, MD 7301 Ohms Lane, Ste 650, Edina, MN 55439 Ph: (952) 835-9880 |
News Archive
Researchers at the University at Buffalo and the University of Pennsylvania were the first to demonstrate that two intracellular events, both stimulated by the same cell receptor, can provoke different behaviors in mammals.
In a preview of a Jan. 24 magazine article, The New York Times reports on Senate Majority Leader Harry Reid's struggle to keep members of his caucus in line on health reform. In December, for instance, Sen. Joseph Lieberman, D-Conn., told a talk show host he would not support the health overhaul plan without significant changes, surprising the majority leader.
A review of contemporary grading systems for prostate cancer has found that modernization of the Gleason grading system results in more accurate grading for radical prostatectomy than older systems.
Scientists from Duke-NUS Medical School have derived a structural model of a transporter at the blood-brain barrier called Mfsd2a. This is the first molecular model of this critical transporter, and could prove important for the development of therapeutic agents that need to be delivered to the brain -- across the blood-brain barrier. In future, this could help treat neurological disorders such as glioblastoma.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths. Deferoxamine Mesylate is therapeutically equivalent to the reference-listed drug Desferal®, which is marketed by the innovator Novartis.
› Verified 7 days ago
James Raymond Bishop, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 6401 France Ave S, Edina, MN 55435 Phone: 952-924-5108 | |
Shaun Adams, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 6401 France Ave, Fairview Southdale Hospital, Edina, MN 55435 Phone: 952-924-5141 Fax: 952-924-5796 | |
Jenny L Thacker, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7301 Ohms Ln, Suite 650, Edina, MN 55439 Phone: 952-835-9880 Fax: 952-857-1554 | |
Todd Joing, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 6401 France Ave S, Fairview Southdale Hospital, Edina, MN 55435 Phone: 952-924-5141 Fax: 952-924-5796 | |
Dr. Lawrence S Scheuer, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7500 France Ave S, Edina, MN 55435 Phone: 952-835-1311 | |
Matthew David Barrett, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 6401 France Ave, Fairview Southdale Hospital, Edina, MN 55435 Phone: 952-924-5141 Fax: 952-924-5796 | |
Christopher Farnan, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7301 Ohms Lane, Suite 650, Edina, MN 55439 Phone: 952-857-1505 |